
Centradol50 mg
Incepta Pharmaceuticals Ltd.
Tapentadol Hydrochloride is an opioid analgesic indicated for the relief of pain, with evidence-based use classified as follows: Established/FDA-Approved Uses Acute pain (immediate-release…
Tapentadol Hydrochloride is an opioid analgesic indicated for the relief of pain, with evidence-based use classified as follows:
Tapentadol Hydrochloride is reserved for pain severe enough to require opioid treatment and for which alternative, non-opioid treatment options are inadequate or not tolerated; it is not intended for use on an as-needed basis for mild pain.
Dosing of Tapentadol Hydrochloride must be individualized based on the severity of pain, patient response, and prior opioid exposure. Use the lowest effective dose for the shortest duration consistent with treatment goals.
| Indication | Formulation | Typical Adult Dosing |
|---|---|---|
| Acute pain | Immediate-release | 50 mg to 100 mg orally every 4 to 6 hours as needed; maximum 700 mg on day one, 600 mg per day thereafter |
| Chronic pain | Extended-release | Initially 50 mg twice daily (approximately every 12 hours); titrate in increments of 50 mg twice daily no more often than every 3 days, up to a maximum of 500 mg/day |
| Diabetic peripheral neuropathic pain | Extended-release | Same titration schedule as chronic pain, individualized to response and tolerability |
| Body Weight | Dose |
|---|---|
| 40-59 kg | 50 mg every 4 hours as needed (maximum single dose 50 mg) |
| 60-79 kg | 50-75 mg every 4 hours as needed (maximum single dose 75 mg) |
| 80 kg or more | 50-100 mg every 4 hours as needed (maximum single dose 100 mg) |
Maximum pediatric daily dose should not exceed 7.5 mg/kg/day. Extended-release Tapentadol Hydrochloride is not established as safe and effective in pediatric patients.
In patients with moderate hepatic impairment, immediate-release Tapentadol Hydrochloride should be initiated at 50 mg no more frequently than every 8 hours; use in severe hepatic impairment and extended-release use in any hepatic impairment is not recommended. Use in severe renal impairment is not recommended.
The most common adverse effects of Tapentadol Hydrochloride (occurring in 10% or more of adult patients) are:
Other commonly reported effects include constipation, headache, pruritus (itching), dry mouth, and fatigue. In pediatric patients, vomiting, constipation, nausea, pruritus, and fever have been reported.
Serious but less common effects include respiratory depression, serotonin syndrome, seizures, severe hypotension, and adrenal insufficiency; see Precautions and Warnings for details.
Tapentadol Hydrochloride is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.